Equity Profile

BSX

Boston Scientific Corporation

Health CareHealth Care Equipment$76.9B

Feb10Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EST

Company Snapshot

Boston Scientific Corporation (BSX) is a global leader in the healthcare equipment sector, specializing in innovative medical devices that improve patient outcomes. With a market cap of $77 billion, the company plays a crucial role in advancing healthcare technology, particularly in areas like cardiology and urology.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and meet demand for its medical devices.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BSX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

In Q1 2026, Boston Scientific reported an EPS of $0.80, matching analyst expectations and resulting in an 8.99% stock increase the following day. The company has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

Management Promises & Guidance

Continued focus on innovative product development.
Commitment to expanding market share in key therapeutic areas.
Ongoing investment in research and development.

Expectations

Wall Street Expectations

Overall expectations for Boston Scientific's upcoming earnings are cautiously optimistic, given their strong track record of beating EPS estimates. Investors will be looking for signs of sustained revenue growth and continued innovation.

Bull Case

If Boston Scientific delivers another EPS beat and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock rally.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about market competition and impact investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this figure will be crucial in determining market sentiment.

How is revenue growth trending in key segments?

Understanding revenue growth in specific therapeutic areas will provide insight into the company's competitive positioning and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Boston Scientific to exceed EPS expectations due to its strong product pipeline and market demand.

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating strong operational execution.

Options pricing suggests a lower expected move compared to historical averages, which could imply an undervaluation of potential volatility.

Recent product launches have received positive feedback, suggesting strong sales momentum.

Key Risk

If revenue growth in key segments exceeds expectations, it could significantly alter the market's perception of the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on whether Boston Scientific can maintain its strong earnings trajectory amid increasing competition in the healthcare equipment sector.

Bull Confirmed If

An EPS of $0.85 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.75 could raise concerns about market share and competitive pressures.

Pre-Earnings Positioning

Options Market

Implied Move

±1.36%

Historical Avg

±5.3%

Pricing cheap

The options market is pricing in a modest move of 1.36%, suggesting that investors are anticipating a relatively stable reaction to the earnings report.

Options are pricing ±1.4% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

59.7%

Calls (28.2M)P/C Ratio: 0.21Puts (7.0M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats expectations, history suggests the stock could rise by approximately 0.45% on the following day, confirming strong demand for its products.

In-Line / Cautious

If the results are in line with expectations, the market may react cautiously, leading to a muted response as investors await further guidance.

Miss

In the event of a miss, history indicates a potential decline of around 5.27% on the following day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on competitive pressures in the healthcare equipment sector.
3Insights into revenue growth trends in specific therapeutic areas.
4Management's outlook on future earnings and market conditions.
5Details on research and development investments and their expected impact.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb8

HMYReported

Harmony Gold Mining Company Limited

RecapView

Feb8

CNAReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and meet demand for its medical devices.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BSX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.92%

Avg Stock Reaction

+0.45%

Last Quarter Recap

Management Promises & Guidance

Continued focus on innovative product development.
Commitment to expanding market share in key therapeutic areas.
Ongoing investment in research and development.

Expectations

Wall Street Expectations

Bull Case

If Boston Scientific delivers another EPS beat and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock rally.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about market competition and impact investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's history of beating EPS estimates, this figure will be crucial in determining market sentiment.

How is revenue growth trending in key segments?

Understanding revenue growth in specific therapeutic areas will provide insight into the company's competitive positioning and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Boston Scientific to exceed EPS expectations due to its strong product pipeline and market demand.

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating strong operational execution.

Options pricing suggests a lower expected move compared to historical averages, which could imply an undervaluation of potential volatility.

Recent product launches have received positive feedback, suggesting strong sales momentum.

Key Risk

If revenue growth in key segments exceeds expectations, it could significantly alter the market's perception of the company's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on whether Boston Scientific can maintain its strong earnings trajectory amid increasing competition in the healthcare equipment sector.

Bull Confirmed If

An EPS of $0.85 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.75 could raise concerns about market share and competitive pressures.

Pre-Earnings Positioning

Options Market

Implied Move

±1.36%

Historical Avg

±5.3%

Pricing cheap

The options market is pricing in a modest move of 1.36%, suggesting that investors are anticipating a relatively stable reaction to the earnings report.

Options are pricing ±1.4% while BSX has averaged ±5.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

59.7%

Calls (28.2M)P/C Ratio: 0.21Puts (7.0M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Boston Scientific beats expectations, history suggests the stock could rise by approximately 0.45% on the following day, confirming strong demand for its products.

In-Line / Cautious

If the results are in line with expectations, the market may react cautiously, leading to a muted response as investors await further guidance.

Miss

In the event of a miss, history indicates a potential decline of around 5.27% on the following day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any commentary on competitive pressures in the healthcare equipment sector.
3Insights into revenue growth trends in specific therapeutic areas.
4Management's outlook on future earnings and market conditions.
5Details on research and development investments and their expected impact.